Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 8;37(2):205-209.
doi: 10.1080/08998280.2024.2301901. eCollection 2024.

Tricuspid regurgitation burden following transcatheter aortic valve replacement requiring early pacemaker implantation

Ghadi Moubarak  1 , Allison T Lanfear  1 , Mohanad Hamandi  1 , Allison I Aldrich  1 , Johanna S Van Zyl  1 , Jasjit K Banwait  1 , Jaccallene V Bomar  1 , Soohyun A Chang  2 , Zuyue Wang  2 , Michael J Mack  1   3 , Molly I Szerlip  2 , Paul A Grayburn  2
Affiliations

Tricuspid regurgitation burden following transcatheter aortic valve replacement requiring early pacemaker implantation

Ghadi Moubarak et al. Proc (Bayl Univ Med Cent). .

Abstract

Background: Conduction abnormality requiring the implantation of a permanent pacemaker (PPM) is a well-known and clinically important complication of transcatheter aortic valve replacement (TAVR). However, PPM implantation may result in lead-associated tricuspid valve regurgitation (TR). This study sought to determine the incidence and progression of TR following PPM implantation after TAVR.

Methods: This was a retrospective review of all echocardiograms of patients who underwent PPM following TAVR at the Baylor Scott & White hospitals from 2012 to 2021. The primary endpoint was TR progression at 30 days and 1 year. A subanalysis comparing the change in TR progression between small and large TAVR devices was also conducted. Secondary outcomes included all-cause death at 30 days and 1 year.

Results: Out of the 2744 patients who underwent TAVR between April 2012 and August 2021, 177 patients (6.5%) subsequently received a new PPM. There was a statistically significant progression of TR at 1-year follow-up (McNemar's P value = 0.02). TR progression rates were comparable between the small and large valve groups at 1-year follow-up (4% vs 11%, P = 0.09, respectively).

Conclusion: In this single healthcare system study, we demonstrated a significant progression of TR in patients with PPM post TAVR at 1 year.

Keywords: Permanent pacemaker; transcatheter aortic valve replacement; tricuspid regurgitation.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Michael Mack: Abbott, trial co-PI; Edwards Life Sciences, trial co-PI; Medtronic, trial study chair. All uncompensated. Molly Szerlip: Edwards LifeSciences, proctor, speaker, consultant; Abbott Vascular, advisory board, consultant, proctor; Medtronic, steering committee; Boston Scientific, speaker, consultant. Paul Grayburn: Research grants, Abbott Vascular, Boston Scientific, Cardiovalve, Edwards Lifesciences, Medtronic, Neochord, Restore Medical, 4 C Medical; consultant/advisory board, Abbott Vascular, Edwards Lifesciences, Medtronic, 4 C Medical. Other authors: Nothing to disclose. The authors report no study-specific funding. They would like to thank Satish and Yasmin Gupta for their unrestricted gift to Baylor Scott & White The Heart Hospital – Plano, for fostering the environment to conduct this research.

Figures

Figure 1.
Figure 1.
Tricuspid regurgitation at baseline, 30 days, and 1 year.
See this image and copyright information in PMC

References

    1. Dowling C, Firoozi S, Panoulas V, et al. . Initial experience of a self-expanding transcatheter aortic valve with an outer pericardial wrap: the United Kingdom and Ireland Implanters’ registry. Catheter Cardiovasc Interv. 2020;95(7):1340–1346. doi:10.1002/ccd.28512. - DOI - PubMed
    1. Al-Bawardy R, Krishnaswamy A, Bhargava M, et al. . Tricuspid regurgitation in patients with pacemakers and implantable cardiac defibrillators: a comprehensive review. Clin Cardiol. 2013;36(5):249–254. doi:10.1002/clc.22104. - DOI - PMC - PubMed
    1. Nona P, Coriasso N, Khan A, et al. . Pacemaker following transcatheter aortic valve replacement and tricuspid regurgitation: a single-center experience. J Card Surg. 2022;37(9):2937–2942. doi:10.1111/jocs.15363. - DOI - PubMed
    1. Marijon E, Trinquart L, Otmani A, et al. . Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator–the EVADEF study. Am Heart J. 2010;159(4):659–664.e1. doi:10.1016/j.ahj.2010.01.011. - DOI - PubMed
    1. Cheng Y, Gao H, Tang L, Li J, Yao L.. Clinical utility of three-dimensional echocardiography in the evaluation of tricuspid regurgitation induced by implantable device leads. Echocardiography. 2016;33(11):1689–1696. doi:10.1111/echo.13314. - DOI - PubMed

LinkOut - more resources